News | August 27, 2024
Mangalam Drugs & Organics awarded US$ 274,800 grant by MMV
The grant is designated for the research and development of Pyronaridine
The grant is designated for the research and development of Pyronaridine
The award recognizes powerful science–industry collaborations for social good
This development will position the company at the forefront of anti- malaria API production globally and is expected to drive substantial growth and profitability
The CALINA study tested a new ratio and dose of Coartem to account for metabolic differences in babies under 5 kg
ZY19489 is a novel anti-malarial compound active against all current clinical strains of P. falciparum and P. vivax, including drug resistant strains
The campaign “Care is Just An Aster Away” was launched along with the unveiling of the new corporate logo on Burj Khalifa on 11th December
Acute therapies continue to report strong growth compared to chronic ones.
Subscribe To Our Newsletter & Stay Updated
